Omniscient Investment Point - Chapter 251



Only Noblemtl

251. Between Stability and Change – 3

(1)

JTS Partners’ Japanese branch is currently doing really well.

Not only its subsidiary Hinome Pharmaceuticals, but also Umi Industries, which has a stake in it, could make a big profit depending on how much is produced in the 7th mine.

Magnetic’s acquisition process also went smoothly, so the 20% stake in the Japanese branch was by no means small.

“I definitely have to support Forte Bio’s Phase 3 approval.”

“But it’s only the Ministry of Food and Drug Safety? It’s not the Japanese Ministry of Health and Welfare or the US FDA.”

“Of course not.”

I smirked at Jo Jeong-hwan, who asked me a question just in case.

In fact, Forte Bio is undergoing Phase 1 clinical trials by the Japanese Ministry of Health, Labour and Welfare and Phase 2a clinical trials by the US FDA.

Word was flowing out that it was obvious that both of them would pass.

So the stock price was steadily rising, and this is what caused the angel people’s anger.

“So, what do you think? Mr. Kang didn’t just give up his stake in Forte Bio because he was losing?”

“what······.”

“Hmm, hum.”

Characteristics of people in investment firms.

When it benefits them, they keep their mouths shut, but when it harms them, their voices grow louder.

Since the two people were the same, I couldn’t help but laugh again.

These shameless authors even go so far as to ask the Japanese branch office in detail about the situation.

“How much was Hinome Pharmaceutical’s sales last year?”

“8 billion yen.”

“Then, is it about 70 billion won or so? Operating profit?”

“It’s 1.2 billion yen.”

“It’s a little over 10 billion. The operating profit margin is about 15%. Well, it’s not bad for a pharmaceutical company.”

Perhaps because he had an accounting background, Choi Sang-soo’s calculations were really fast.

But he missed something, so I quickly provided additional information.

“At the time of acquisition two years ago, sales were 4 billion yen.”

“Huh? So, sales doubled?”

“Yes, that’s right. And at that time, the operating profit was 400 million yen.”

“Wow, operating profit has tripled. And that’s only because of pharmaceuticals, not bio.”

“That’s right. It’s also because the market share for eye diseases has increased from 40% to 50%, and we’re also expanding our range of hepatitis treatments. In addition, health functional foods such as Cordyceps sinensis are selling very well.”

“Let’s just wait and see. Could it be that Cordyceps Militaris is going in there······?”

“It’s supplied by Daeil Farm.”

“ah······.”

This marked the moment when the potential of the Japanese market for Daiichi Farm was recognized at once.

Jo Jeong-hwan’s question was slightly different in direction.

“Are you thinking of just imposing restrictions?”

“Of course not. We are also investing in a company that cultivates artificial pluripotent stem cells. We are even considering acquiring it later. We are also on the verge of acquiring Multi-Poten. Oh, that company is where Yuta Kimura, the current CEO, was the CEO. You can think of it as acting as a broker between the Ministry of Health, Welfare and Welfare and pharmaceutical and bio companies.”

“ah······.”

As my explanation flowed out, exclamations flowed out from both of their mouths one after another.

The questions didn’t stop there.

Next, while asking about the Umi industry, we naturally came across the underground resources of the 7th mine, and finally, the magnetic field came out.

“This is it, oh······. With just Hinome Pharmaceuticals and Umi Industries, it’s no joke, so how much bigger can Magnetic get?”

“Yes. I really need to start praying today. Please pray that Forte Bio’s Osisertinib Phase 3 trial passes quickly.”

But these words became a seed.

A few days later, the news that Osisertinib had passed the phase 3 trial was posted in bold on the stock portal.

『Forte Bio, Finally Done! Osisertinib is on its way to commercialization!』

Was that why?

I received a call from the representative, Park Joo-young.

– Can I see it for a moment?

Without hesitation, I headed straight for Forte Bio.

(2)

First, when I read the emotions engraved on Park Joo-young’s face, it seemed like two things were intersecting.

One was emotion or pride.

“I feel like I’ve really lived for today.”

The other was hesitation.

“But I have a problem.”

“which······?”

“CEO Jang, you know that moving from KOSDAQ to KOSPI is trendy these days?”

“hmm······.”

When I burst into laughter, he asked with a dark expression on his face.

“Why not?”

“No, that’s not it. It’s just a little disappointing.”

“Are you sad? What?”

“Originally, I was a KOSDAQ supporter.”

What I say is true.

As all investors know, there are two domestic stock markets.

One is KOSPI, which trades stocks of major Korean companies, and its relative stability is guaranteed.

The other was KOSDAQ, where relatively small companies are listed.

In particular, it could be said to be a cradle for startups with high growth potential.

The model is, of course, Nasdaq.

However, its status and position are very different from Nasdaq.

In the United States, the New York Stock Exchange is in a similar position to KOSPI, but these days, NASDAQ is more popular than that.

Tesla and others also wanted to stick to NASDAQ’s flagship stocks and did not want to become a New York Stock Exchange signboard.

For some reason, I think NASDAQ symbolizes growth and innovation.

“Wow, why wouldn’t I have cheered for them? Honestly, I don’t know how many times I’ve been telling my friends that KOSDAQ is Korea’s NASDAQ.”

“yes······.”

“But ideals and reality are different. Maybe it’s because I’m older now, but I would like to challenge myself in a stable way.”

Some may call this a weak statement, but I can totally understand it.

Funds flow into KOSPI much more stably than into KOSDAQ.

Even if that weren’t the case, volatility was relatively low.

So, when a company on the KOSDAQ experiences repeated surges and crashes, the CEO’s mentality often breaks down.

It was probably the same this time too.

Before the Phase 3 announcement today, rumors of Forte Bio were circulating somewhere.

Someone’s delusion that the failure of the MFDS Phase 3 trial might lead to delisting was gaining strength.

Eventually, this unfounded rumor spread rapidly through YouTube, and Forte Bio had to issue a public statement denying the rumor.

As I was going up and down YouTube, the stock price fell 25% in a week.

“I even thought about whether I should appear on Echo Trend recently. I finished at the upper limit today, but I feel like I’ve aged 10 years in a week.”

“I understand. I completely understand.”

I nodded.

A while ago, I saw an article that said investors were setting up camp not only in front of the seedbed but also in front of the company.

They also couldn’t help but understand that they were investing their valuable assets in Forte Bio.

But now that I’ve reached the point of collapse, I can’t help but lose my mind.

“I think it has entered the 3-phase stabilization phase now, but I am not very happy about seeing the upper limit today. The stock price will probably fluctuate tomorrow and the day after. But what if it crashes again due to rumors? Then investors will not leave me alone mentally.”

“I don’t think going to KOSPI will solve it.”

“It’s better than KOSDAQ. You know this, too.”

“That’s true.”

I couldn’t stop Park Joo-young from moving to KOSPI, even if it was just to reduce stress.

Sometimes humans can make any choice they want to escape from mental pain.

“Then I understand that we will proceed like that.”

“Thank you and I’m sorry.”

“Hey, don’t say that.”

Park Joo-young’s face was filled with an apologetic expression, so I smiled indifferently and stood up from my seat.

And the next day, the article came out.

『Forte Bio, pushing for listing before KOSPI!』

The market went wild.

Forte Bio, which experienced a drop from a market cap of 5 trillion won, showed off its prowess by hitting the upper limit for two consecutive days.

This wasn’t the end.

A week later, it had doubled.

“Wow, the market cap will soon exceed 10 trillion.”

“I know.”

I smiled bitterly at Chief Secretary Kwak Hyeon-woo’s words.

This time it was overheated.

If it surges to this extent, it is no exaggeration to say that expectations for listing before KOSPI have also been raised.

‘Should I say thank you for this?’

Our stake in Bio Forte has increased to 3%, so its value has increased to 300 billion won.

Looking at this, it seems that there is no such thing as complete stability or definite change.

It’s just somewhere between stability and change······.

‘Still, I support the representative’s mentality.’

Furthermore, I also support Forte Bio’s infinite growth in the future.

(3)

Should we say that good news always comes all at once?

I received a call from Myungjuwon in Japan.

– Sir, I’m leaving.

“Oh, yes yes. It’s been a while. Hahaha.”

– I just wanted to tell you some good news.

“Huh? What is it? Is the magnetic field test finished?”

– No, uh······. There’s still no news about that.

The right of first refusal for the acquisition of Magnetic was won through a consortium bid by our JTS and Hyun Ki-hyuk’s H2K.

Since then, negotiations for an acquisition and sale have almost certainly taken place, but due diligence is still ongoing.

For reference, the actual investigation was entrusted to a local company because it seemed like it would be more accurate.

Of course, it was through the Japanese branch of JTS, so I thought that was why he called, so I sounded happy.

– I heard that Japanese kids are really thorough in their fieldwork, but it’s taking too long. Anyway, I think we’ll have to wait a little longer. I’m contacting you now to tell you that Forte Bio’s Osisertinib has passed the Ministry of Health and Welfare’s Phase 1 clinical trial.

“uh?”

– Representative Park probably heard the news by now.

“Yes, hahaha.”

At this point, it would not be an exaggeration to say that things were going well.

‘The advance into Japan has nothing to do with Pie, you know.’

Forte Bio transferred its liver cancer candidate, ocisertinib, to global pharmaceutical company Pfizer for a technology fee of 1 trillion won.

However, the content of the contract was not very good.

If it passes Phase 3, the profits of ocisertinib sold in the US would be 85% Pfizer and 15% Forte Bio.

Korea was also 5:5.

Fortunately, since no other countries were included, I applied for the first prize to the Japanese Ministry of Health, Labour and Welfare with the mindset that it would be a win-win even if I lost.

‘What if we pass the 3rd phase here?’

Although some of the ocisertinib sold in Japan is given to the distributing pharmaceutical company, it is 100% Forte Bio’s.

Even the distributor was Hinome Pharmaceutical.

That is, I am in a situation where I can see you and also get the mulberry.

“Good. Forte Bio is already good these days, but it looks like it’s going to taste even better.”

– Yes, yes, I heard the news there too. I heard it passed phase 3 at the Ministry of Food and Drug Safety?

“you’re right.”

– This will likely pass through all three countries, Korea, the US, and Japan soon, right?

“Hey, I heard Japan is really picky.”

– It’s not like that these days. Anyway, please look forward to it. Hahaha.

“all right.”

After talking to this point, I quickly contacted Park Joo-young.

He was busy and kept on the phone, but I was able to find out what he was feeling through the news that afternoon.

『Forte Bio’s Ocigertinib Passes Phase 1 Trial in Japan’s Ministry of Health, Labour and Welfare!』

A photo of a delighted Park Joo-young was posted with a title that said “breaking news.”